|Bid||4.6600 x 1300|
|Ask||4.6500 x 2200|
|Day's range||4.0000 - 4.8995|
|52-week range||0.3600 - 11.4000|
|Beta (5Y monthly)||3.42|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2021 - 17 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.00|
Shares of CBAK Energy Technology (NASDAQ: CBAT) had jumped an astounding 16.2% by 11:35 a.m. EST on Friday after the Chinese battery maker announced the invention of a new Special 26650 battery designed for use in ultra-low temperatures. As CBAK explained, the new battery is a variation of its current 26650 lithium rechargeable battery. Currently in "trial production," the Special 26650 battery is said to be exhibiting satisfactory test results so far.
CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced that it has started the trial production of its special 26650 lithium battery (the "Special 26650 Battery"). Different from our regular 26650 batteries that the company is currently manufacturing and selling, the Special 26650 Battery is a self-developed battery model specifically designed for application in ultra-low temperature environments. The Special 26650 Battery has delivered satisfactory test performance results to date, while the trial's production yield rate has also been very close to our required level for mass production. The Company believes that it will be capable of achieving mass delivery of its Special 26650 Battery by the second half of 2021.
CBAK Energy Technology, Inc. ("CBAK Energy," or the "Company," NASDAQ: CBAT), a leading lithium-ion battery manufacturer and electric energy solution provider, today announced that it closed a registered direct placement of approximately $70 million of its common stock, priced at the market under applicable Nasdaq rules with a price of $7.83 per share, and the concurrent private placement on February 10, 2021, as previously announced on February 8, 2021. The Company issued a total of 8,939,976 shares of common stock to certain institutional investors. The Company also issued Series A-1 Warrants to the investors to purchase a total of 4,469,988 shares of common stock and Series A-2 Warrants to purchase up to 2,234,992 shares of common stock, both of which were issued at an exercise price of $7.67 per share. Series A-1 Warrants and Series A-2 Warrants are exercisable for 42 months and 45 months, respectively, from the issue date. In addition, the Company issued Series B Warrants to the same investors to purchase a total of 4,469,988 shares of common stock at an exercise price of $7.83 per share, which are exercisable for 90 days from the issue date.